Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Datamonitor
|
$175.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Amgen, Inc. Completes Acquisition of KAI Pharmaceuticals
Amgen, Inc. announced the completion of the acquisition of KAI Pharmaceuticals, a privately held company based in South San Francisco. The acquisition was initially announced April 10, 2012 and includes KAI's lead product candidate KAI-4169, which is a agent being studied initially for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis. Terms of the transaction were not disclosed.
Latest Developments for Amgen Inc
- Amgen Inc Announces Positive Results From Talimogene Laherparepvec Phase 3 Study In Patients With Metastatic Melanoma
- Amgen Inc Reaffirms FY 2013 Guidance-Conference Call
- Astellas Pharma Inc to Establish Joint Venture with Amgen Inc.
- Amgen Inc Reaffirms FY 2013 Revenue Guidance; Raises FY 2013 EPS Guidance
Latest Key Developments in Biotechnology
- Nektar Therapeutics Announces Positive Data From Human Abuse Liability Study For NKTR-181
- Amarantus Bioscience Holdings Inc Reports Positive Results On MANF Neuroprotective Properties Demonstrated In Preclinical Study In China
- BioInvent International AB Implements Rights Issue of Approximately SEK 22 Million; Updates on New CEO Start Date
- Newron Pharmaceuticals SpA's sNN0031 Proves Safety and Efficacy in Phase I/II Study in Parkinson's Disease
- Share this
- Link this
- Digg this
Follow Reuters